AmerisourceBergen Announces Organizational Changes.

VALLEY FORGE, Pa. -- AmerisourceBergen Corporation (NYSE: ABC) today announced organizational changes, effective September 1, 2009, to better position the Company to continue to achieve its long-term financial goals.

Steven H. Collis will become Executive Vice President AmerisourceBergen and President of AmerisourceBergen Drug Corporation (ABDC), the Company's largest subsidiary. Collis was previously Executive Vice President and President of AmerisourceBergen Specialty Group (ABSG). He led ABSG from a start-up company in 1994 to the approximately $15 billion subsidiary it is today. In his new role, he will lead the ABDC organization. He continues to report directly to R. David Yost, President and Chief Executive Officer of AmerisourceBergen Corporation.

"ABDC has been very successful since we began running it with Executive Vice President and Chief Financial Officer Mike DiCandilo leading operations and me leading sales and marketing," said Yost. "To drive future performance, we are consolidating those functions under one leader, and I am very pleased that Steve Collis will be applying his substantial management talent to lead ABDC. At the same time, Mike DiCandilo will continue his corporate role with ABDC in finance, supply chain management and our very important Business Transformation ERP project. The result will be an even more focused organization."

Michael D. DiCandilo, continues as Executive Vice President and Chief Financial Officer of AmerisourceBergen, with on-going responsibility for all corporate financial operations, supply chain management, AmerisourceBergen Packaging Group, and information technology, including the Company's Business Transformation ERP project. He continues to report directly to Yost.

Michael A. Mullen will lead ABSG as Chief Operating Officer, AmerisourceBergen Specialty Group, also reporting directly to Yost. Prior to his new assignment, Mullen, who has been with ABSG for six years, was President of Distribution Services at ABSG, previously served as the chief financial officer for the subsidiary, and has been a key force behind the long-running success of ABSG.

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services companies serving the United States, Canada and selected global markets. Servicing both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. AmerisourceBergen's service solutions range from pharmacy automation and pharmaceutical packaging to reimbursement and pharmaceutical consulting services. With more than $70 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 10,000 people. AmerisourceBergen is ranked #26 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements about AmerisourceBergen's future business and financial performance, estimates and prospects. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in any forward-looking statements: changes in pharmaceutical market growth rates; the loss of one or more key customer or supplier relationships; changes in customer mix; customer delinquencies, defaults or insolvencies; supplier defaults or insolvencies; changes in pharmaceutical manufacturers' pricing and distribution policies or practices; adverse resolution of any contract or other dispute with customers or suppliers; federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; changes in U.S. legislation or regulatory action affecting pharmaceutical product pricing or reimbursement policies, including under Medicaid and Medicare; changes in regulatory or clinical medical guidelines and/or labeling for the pharmaceuticals we distribute, including certain anemia products; price inflation in branded pharmaceuticals and price deflation in generics; significant breakdown or interruption of our information technology systems; our inability to implement an enterprise resource planning (ERP) system to handle business and financial processes within AmerisourceBergen Drug Corporation's operations and our corporate functions without operating problems and/or cost overruns; success of integration, restructuring or systems initiatives; interest rate and foreign currency exchange rate fluctuations; economic, business, competitive and/or regulatory developments in Canada, the United Kingdom and elsewhere outside of the United States, including potential changes in Canadian provincial legislation or regulatory action to lower pharmaceutical product pricing and service fees; the impact of divestitures or the acquisition of businesses that do not perform as we expect or that are difficult for us to integrate or control; our inability to successfully complete any other transaction that we may wish to pursue from time to time; changes in tax legislation or adverse resolution of challenges to our tax positions; increased costs of maintaining, or reductions in our ability to maintain, adequate liquidity and financing sources; continued volatility, and further deterioration of the capital and credit markets; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting our business generally. Our most recent annual report on Form 10-K, quarterly reports on Forms 10-Q and current reports 8-K (which we may revise or supplement in future reports filed to the SEC) provide additional information about these risks, uncertainties and other matters. We do not undertake to update our forward-looking statements.